Patient and disease characteristics
Characteristic . | No. (%) . |
|---|---|
| Sex | |
| Male recipients | 58 (61) |
| Male donors | 55 (59) |
| Sex match | |
| Female > male | 68 (72) |
| CMV serology | |
| Donor positive | 36 (38) |
| Recipient positive | 55 (58) |
| Diagnosis | |
| Acute myeloid leukemia | 12 (13) |
| Acute lymphoblastic leukemia | 21 (22) |
| Chronic myelogenous leukemia* | 33 (35) |
| Myelodysplastic syndrome | 10 (10) |
| Aplastic anemia† | 13 (14) |
| Lymphoma‡ | 4 (3) |
| Other§ | 2 (2) |
| Disease risk∥ | |
| High risk | 64 (67) |
| Conditioning regimen | |
| TBI based | 45 (47) |
| Intensified conditioning¶ | 66 (69) |
| Including ATG | 32 (34) |
| GvHD prophylaxis | |
| Cyclosporine + methotrexate | 72 (76) |
| Cyclosporine + prednisone | 10 (11) |
| Cyclosporine alone | 12 (13) |
| T-cell depletion | 11 (12) |
| Source of cells | |
| Bone marrow | 68 (72) |
| Peripheral blood | 19 (20) |
| Cord blood | 8 (8) |
| Donor type | |
| HLA-identical sibling | 62 (65) |
| Unrelated | 29 (31) |
| Mismatched related | 4 (4) |
Characteristic . | No. (%) . |
|---|---|
| Sex | |
| Male recipients | 58 (61) |
| Male donors | 55 (59) |
| Sex match | |
| Female > male | 68 (72) |
| CMV serology | |
| Donor positive | 36 (38) |
| Recipient positive | 55 (58) |
| Diagnosis | |
| Acute myeloid leukemia | 12 (13) |
| Acute lymphoblastic leukemia | 21 (22) |
| Chronic myelogenous leukemia* | 33 (35) |
| Myelodysplastic syndrome | 10 (10) |
| Aplastic anemia† | 13 (14) |
| Lymphoma‡ | 4 (3) |
| Other§ | 2 (2) |
| Disease risk∥ | |
| High risk | 64 (67) |
| Conditioning regimen | |
| TBI based | 45 (47) |
| Intensified conditioning¶ | 66 (69) |
| Including ATG | 32 (34) |
| GvHD prophylaxis | |
| Cyclosporine + methotrexate | 72 (76) |
| Cyclosporine + prednisone | 10 (11) |
| Cyclosporine alone | 12 (13) |
| T-cell depletion | 11 (12) |
| Source of cells | |
| Bone marrow | 68 (72) |
| Peripheral blood | 19 (20) |
| Cord blood | 8 (8) |
| Donor type | |
| HLA-identical sibling | 62 (65) |
| Unrelated | 29 (31) |
| Mismatched related | 4 (4) |
Including 16 patients who received grafts in first chronic phase; 13 in accelerated phase, and 4 in blast crisis.
Five patients with idiopathic aplastic anemia, 3 with paroxysmal nocturnal hemoglobinuria, and 5 with Fanconi anemia.
Two patients with high-grade lymphoma, 1 with low-grade lymphoma, and 1 with Hodgkin disease.
Myelofibrosis in 2 patients.
Patient with chronic myelogenous leukemia first chronic phase, acute leukemia in first remission, and patient with acquired aplastic anemia were considered as having low-risk diseases; all other patients were considered as having high-risk diseases.
Standard conditionings were cyclophosphamide with either busulfan or TBI or cyclophosphamide plus ATG (in aplastic anemia). All other conditionings were considered as intensified conditioning regime.